Bearz相关文献与解析，生知库 | 链接生命科学的每一步

Torresan, Sara; Bortolot, Martina; Bertoli, Elisa; Del Conte, Alessandro; Stanzione, Brigida; de Carlo, Elisa; Schiappacassi, Monica; Spina, Michele; Baldassarre, Gustavo; Bearz, Alessandra

肺癌

肿瘤

肿瘤免疫

Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study

劳拉替尼治疗既往接受过ALK抑制剂治疗的ALK阳性转移性非小细胞肺癌患者：一项IV期研究的结果

期刊:Future Oncology

影响因子:2.6

doi:10.1080/14796694.2026.2653679

Bearz, Alessandra; Ricciardi, Serena; Vivek Raut, Nirmal; Dols, Manuel Cobo; Chiradoni Thungappa, Satheesh; Sacco, Paola Claudia; Thurm, Holger; Pavlov, Dmitri; Toffalorio, Francesca; Felip, Enriqueta

Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer

心脏问题：靶向治疗在致癌基因依赖性非小细胞肺癌中的心脏毒性

期刊:International Journal of Molecular Sciences

影响因子:4.9

doi:10.3390/ijms26020554

Torresan, Sara; Bortolot, Martina; De Carlo, Elisa; Bertoli, Elisa; Stanzione, Brigida; Del Conte, Alessandro; Spina, Michele; Bearz, Alessandra

Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches

致癌基因依赖型非小细胞肺癌的免疫疗法：证据和治疗方法

期刊:International Journal of Molecular Sciences

影响因子:4.9

doi:10.3390/ijms26020583

Foffano, Lorenzo; Bertoli, Elisa; Bortolot, Martina; Torresan, Sara; De Carlo, Elisa; Stanzione, Brigida; Del Conte, Alessandro; Puglisi, Fabio; Spina, Michele; Bearz, Alessandra

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

CONTACT-01：一项随机 III 期试验，比较阿特珠单抗联合卡博替尼与多西他赛治疗接受过免疫检查点抑制剂和化疗后的转移性非小细胞肺癌的疗效

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO.23.02166

Neal, Joel; Pavlakis, Nick; Kim, Sang-We; Goto, Yasushi; Lim, Sun Min; Mountzios, Giannis; Fountzilas, Elena; Mochalova, Anastasia; Christoph, Daniel C; Bearz, Alessandra; Quantin, Xavier; Palmero, Ramon; Antic, Vladan; Chun, Elaine; Edubilli, Tirupathi Rao; Lin, Ya-Chen; Huseni, Mahrukh; Ballinger, Marcus; Graupner, Vilma; Curran, Dominic; Vervaet, Piet; Newsom-Davis, Thomas

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance

应对BRAF突变型非小细胞肺癌的治疗挑战：非V600突变、免疫疗法及克服耐药性

期刊:International Journal of Molecular Sciences

影响因子:4.9

doi:10.3390/ijms252312972

Bortolot, Martina; Torresan, Sara; De Carlo, Elisa; Bertoli, Elisa; Stanzione, Brigida; Del Conte, Alessandro; Spina, Michele; Bearz, Alessandra

Targeted Therapy in Mesotheliomas: Uphill All the Way

间皮瘤靶向治疗：一路披荆斩棘

期刊:Cancers

影响因子:4.4

doi:10.3390/cancers16111971

Bertoli, Elisa; De Carlo, Elisa; Bortolot, Martina; Stanzione, Brigida; Del Conte, Alessandro; Spina, Michele; Bearz, Alessandra

发表日期：2024

文献求助收藏

Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial

阿特珠单抗联合卡铂和依托泊苷治疗未经治疗的广泛期小细胞肺癌患者：MAURIS IIIb期试验的中期结果

期刊:Oncologist

影响因子:4.2

doi:10.1093/oncolo/oyad342

Bria, Emilio; Morgillo, Floriana; Garassino, Marina Chiara; Ciardiello, Fortunato; Ardizzoni, Andrea; Stefani, Alessio; Verderame, Francesco; Morabito, Alessandro; Chella, Antonio; Tonini, Giuseppe; Gilli, Marina; Del Signore, Ester; Berardi, Rossana; Mencoboni, Manlio; Bearz, Alessandra; Delmonte, Angelo; Migliorino, Marta Rita; Gridelli, Cesare; Pazzola, Antonio; Iero, Manuela; De Marinis, Filippo

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

评估洛拉替尼对晚期非小细胞肺癌患者CYP2B6、CYP2C9、UGT和P-糖蛋白底物的影响

期刊:Clinical Pharmacokinetics

影响因子:4

doi:10.1007/s40262-023-01309-4

Chen, Joseph; Bearz, Alessandra; Kim, Dong-Wan; Mamdani, Hirva; Bauman, Jessica; Chiari, Rita; Ou, Sai-Hong Ignatius; Solomon, Benjamin J; Soo, Ross A; Felip, Enriqueta; Shaw, Alice T; Thurm, Holger; Clancy, Jill S; Lee, Kimberly; O'Gorman, Melissa; Tanski, Cherie; Pithavala, Yazdi K

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

在PD-L1未选择的转移性非小细胞肺癌患者中，斯帕塔利珠单抗联合铂类双药化疗，可联合或不联合卡那单抗。

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-024-12841-2

Santoro, Armando; Pilar, Garrido; Tan, Daniel S W; Zugazagoitia, Jon; Shepherd, Frances A; Bearz, Alessandra; Barlesi, Fabrice; Kim, Tae Min; Overbeck, Tobias R; Felip, Enriqueta; Cai, Can; Eddy, Simantini; McCulloch, Tracey; Schaefer, Eric S

BRAF class II-III mutations in NSCLC: a single center experience

非小细胞肺癌中BRAF II-III类突变：单中心经验

Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study

劳拉替尼治疗既往接受过ALK抑制剂治疗的ALK阳性转移性非小细胞肺癌患者：一项IV期研究的结果

Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer

心脏问题：靶向治疗在致癌基因依赖性非小细胞肺癌中的心脏毒性

Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches

致癌基因依赖型非小细胞肺癌的免疫疗法：证据和治疗方法

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

CONTACT-01：一项随机 III 期试验，比较阿特珠单抗联合卡博替尼与多西他赛治疗接受过免疫检查点抑制剂和化疗后的转移性非小细胞肺癌的疗效

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance

应对BRAF突变型非小细胞肺癌的治疗挑战：非V600突变、免疫疗法及克服耐药性

Targeted Therapy in Mesotheliomas: Uphill All the Way

间皮瘤靶向治疗：一路披荆斩棘

Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial

阿特珠单抗联合卡铂和依托泊苷治疗未经治疗的广泛期小细胞肺癌患者：MAURIS IIIb期试验的中期结果

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

评估洛拉替尼对晚期非小细胞肺癌患者CYP2B6、CYP2C9、UGT和P-糖蛋白底物的影响

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

在PD-L1未选择的转移性非小细胞肺癌患者中，斯帕塔利珠单抗联合铂类双药化疗，可联合或不联合卡那单抗。